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ABSTRACT 
 
Objective:  The objective of this selective EBM review is to determine whether or not “Do oral 
probiotics in conjunction with fluconazole reduce symptoms among patients suffering from 
vulvovaginal candidiasis (VVC)?” 
Study design: Systematic review of three randomized controlled trials published in 2009 and 
2012. 
Data sources: Three randomized controlled trials published in peer-reviewed journals comparing 
the effects of fluconazole in conjunction with probiotics in the treatment of VVC. Data sources 
found using Embase, EMBScohost, and CINAHL 
Outcomes measured:  Outcomes were measured based on patients reporting of: decrease in 
dysuria symptoms at 5-7 days post treatment, resolution of abnormal odorless cheese like vaginal 
discharge, dyspareunia, dysuria, and localized vulvovaginal irritation with VVC at 7 days post 
treatment, and decrease in vaginal discharges associated with at least one of the following 
(itching and burning vaginal feeling, dyspareunia and dysuria) at 4 weeks post treatment. All 
results were examined to determine whether or not oral probiotics in conjunction with 
fluconazole resulting in a significant difference in symptom reduction of VVC.  
 
Results: In both Nouraei et al. and Martinez et al., oral probiotics in conjunction with fluconazole 
showed a statistically significant different and proved to be an effective treatment in reducing the 
symptoms associated with VVC (p= 0.02 and 0.03 respectively). Due to issue faced by the study 
design in the RCT by Anukam et al., a statistically significant difference was unable to be found 
when determining a reduction of VVC symptom (p=0.28). 
Conclusions: Results of these RCT showed conflicting results. While both Nouraei et al. and 
Martinez et al. indicated that oral probiotics in conjunction with fluconazole was an effective 
treatment in the reduction of VVC symptoms Anukam et al. was unable to show a statistically 
significant difference due to loss of follow up. Further studies with more strict protocol and a 
larger sample size need to be explored in the future in order to reach more definitive answers.  
Keywords: Vulvovaginal Candidiasis; Probiotics; Fluconazole 
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INTRODUCTION 
 Vulvovaginal candidiasis (VVC) is a vaginal infection caused by the overgrowth of 
naturally occurring Candida species due to a fluctuation in the normal environment and flora of 
the vagina.1 Probiotics are supplements containing living microorganisms which are naturally 
found in the body.2 It is thought that the use of these products may be beneficial in restoring the 
body’s natural environment to base line. This systematic review evaluates three double blind, 
randomized, controlled trials comparing the efficacy of oral probiotic use in combination with 
fluconazole for the treatment of VVC in comparison to those being treated with fluconazole 
alone. 
With the high incidence of VVC it is important that physician assistants have a firm 
understanding of this disorder and functional treatment methods to provide the best patient 
outcomes. Statistics show that 75% of women suffer from VVC at least once during their lives, 
45% of those women experience VVC twice or more annually and 5% are diagnosed with 
chronic and recurrent infections.2 Recurrent VVC is defined as >4 episodes of VVC in a 12 
month period.3 
Diagnosis and treatment of VVC in addition to the lost wages accrued by decreased work 
productivity resulted in a total cost of around $1.8 billion in 1995 and rose to $3.1 billion in 
2014.4 While an exact estimate pertaining to VVC alone is not available, it has been determined 
that roughly 5 to 10 million office visits per year are attributed to vaginitis.5  With VVC being 
the second most common documented cause of vaginitis, after bacterial vaginosis,4 one can 
imagine this number is quite high. 
There are several etiological variations of Candida which result in VVC. 80-90% of cases 
have been found to be due to Candida albicans, 5-15% are due to Candida glabrata,2 and a small 
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percentage are due to Candida tropicalis.5 The overgrowth of these Candida species results in 
varying symptoms including: thick, white, vaginal discharge, vulvovaginal itching, burning, and 
dysuria.4 
Standard treatment of symptomatic disease includes either oral medications or topical 
vaginal suppositories and creams. For women with infrequent VVC, over the counter 
preparations of miconazole or clotrimazole for 3-10 days are first line treatment.5 Although 
topical treatments have traditionally been first line treatment, they are slightly hindered by 
decreased compliance due to longer treatment courses and the discomfort caused by the manner 
in which they are absorbed.1 Based on this, oral treatment with fluconazole 150 mg PO for 1 day 
5 is becoming increasingly more common. Azole antifungal medications have been proven to 
relieve symptoms and result in a negative culture in 80-90% of cases.1 The use of oral probiotics 
in conjunction with tradition treatment methods, like fluconazole, may be used to reduce the 
symptoms associated with VVC and increase the effectiveness of antifungal treatment.  
Researchers believe that VVC and its traditional forms of treatment may lead to a 
destruction of existing vaginal flora.2,4 This may result in prolonged symptoms and secondary 
opportunistic vaginal infections. Due to the known benefits of probiotics, it is thought that they 
may be quite valuable in the treatment of VVC. Previous studies have proven the benefit of 
intravaginal probiotic usage in the prevention of VVC and other vaginal infections by 
strengthening the natural vaginal flora.2 Lactobacillus and Bifidobacterium are two prevalent 
microorganisms within the vaginal and are the focus of many probiotic treatments. Due to the 
high incidence of VVC and frequent use of traditional treatments, oral probiotics are being 
proposed as an adjunctive measure to treating VVC in a hope to improve the therapeutic 
efficacy. 
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OBJECTIVE 
 The objective of this selective EBM review is to determine whether or not “Do oral 
probiotics in conjunction with fluconazole reduce symptoms among patients suffering from 
vulvovaginal candidiasis (VVC)?” 
METHODS 
Three randomized, double blind, placebo controlled clinical trials with specific 
population, intervention, comparison, and outcomes were selected for this systematic review. All 
studies focused on a population of non-pregnant women diagnosed with symptomatic VVC. The 
intervention which was studies was the use of oral probiotics in combination with fluconazole in 
comparison to the use of a placebo pill in combination with fluconazole. These variants were 
used to measure the outcome of reduced symptoms associated with VVC.  
All articles were published in English written peer-reviewed journals and found by 
myself using the Embase, EBScohost, and CINAHL databases. All studied were discovered 
using the keywords “vulvovaginal candidiasis”, “probiotics” and “fluconazole”. All studies were 
selected based on their relevance to the topic and whether or not they included patient oriented 
evidence that matters (POEMs). The inclusion criteria used for this review were RCTs published 
after 2007 that discussed the efficacy of oral probiotics in combination with fluconazole as a 
treatment method for VVC. Exclusion criteria included pregnant patients suffering from VVC as 
well as patients suffering from a combination of vaginal infections at the same time as a VVC 
infection. The statistical significance of the study outcomes were determined using relative 
benefit increase (RBI), absolute benefit increase (ABI), number needed to treat (NNT), number 
needed to harm (NNH) and p- value. The specific studies demographics and characteristics are 
outlined in Table 1. 
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TABLE 1: Demographics and characteristics of included studies 
Study Type # Pts Age 
(yrs) 
Inclusion Criteria Exclusion Criteria W/
D 
Intervention 
Nouraei 
(2012)2 
RCT, 
double 
blind, 
placebo-
controlled 
 
102 18-40 ▪ women ages 18–
40 
▪ married; in a 
monogamous 
relationship 
▪ receiving 
clotrimazole 
without 
improvement 
▪ positive KOH 
samples in culture  
▪ diagnosed VVC 
with itching, 
cheesy vaginal 
discharge, dysuria, 
pH <4.5, 
dyspareunia, vulvar 
erythema, or vulvar 
edema 
 
▪ pregnant, 
lactating, or 
menstruating  
▪ using any vaginal 
medication, 
antibiotics, 
immunosuppressive 
drugs, or exogenous 
hormones during 
the 2 weeks prior to 
the study 
▪intercourse or 
vaginal douche in 
the previous 24 hr 
▪ positive 
trichomonal or 
bacterial vaginosis 
infections 
▪ known systemic 
disease 
12 Treatment of 
vulvovaginal 
candidiasis 
with a 
combination of 
fluconazole 
and oral 
Protexin for 10 
days 
Anukam 
(2009)3 
RCT, 
double 
blind, 
placebo- 
control 
59 18-50 ▪ Women between 
18-50 
▪History of VVC 
with >3 episodes 
over the previous 
12 months 
▪symptomatic at 
presentation  
 
▪ Women with 
evidence of other 
urogenital 
infections 
▪ pregnant women 
33 Lactobacillus 
rhamnosus 
GR-1 and 
Lactobacillus 
reuteri RC-14  
with 
fluconazole 
treatment for 3 
months 
Martinez 
(2009)4 
RCT, 
double 
blinded, 
placebo-
controlled 
 
55 16-46 ▪ Women suffering 
from vaginal 
discharge 
associated itching 
and burning, 
dyspareunia or 
dysuria 
▪ Positive Candida 
culture 
▪ Pregnant or 
menstruating  
▪ Positive for HIV, 
BV, or 
trichomoniasis 
▪ Use of antibiotic/ 
anti-fungal agents 
within 2 weeks  
▪ fluconazole 
allergy 
 Fluconazole 
with two 
probiotic 
capsules 
(containing 
Lactobacillus 
rhamnosus 
GR-1 & 
Lactobacillus 
reuteri RC-14) 
for 4 weeks  
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OUTCOMES MEASURED  
 All selected RCT examined the effectiveness of oral probiotics in conjunction with 
fluconazole in the treatment of VVC by measuring a reduction in reported symptoms. This 
systematic review evaluates the outcomes that matter to patients in each RCT. 
 In all three RCT participants improvement was measuring based on patients subjective 
impression and their reporting of a decrease in symptoms.  
 Study outcomes in the RCT by Nouraei et al. were measured 5-7 days after the start of 
treatment based on patient reporting reduced dysuria associated with VVC when comparing the 
fluconazole + placebo group to the fluconazole + protexin group.   
 
Anukam et al. focuses on the resolution of symptoms by day 7 of treatment through the 
use of a questionnaire which asked participants to log the day on which they obtained symptom 
relief. Symptoms in this study were defined as abnormal, odorless, vaginal discharge, 
dyspareunia, dysuria, and localized irritation or discomfort to the vulvovaginal area.  
Martinez et al. measured resolution of vaginal discharge associated with at least one of 
the following symptoms: dyspareunia, dysuria and itching or burning vaginal sensation on day 
28 of treatment based on patient report. 
RESULTS 
 This systematic review examined three RCT comparing the effectiveness of oral 
probiotics in conjunction with fluconazole in the treatment of VVC.  Each RCT studied non-
pregnant women suffering from symptomatic VVC who had not been diagnosed with any other 
vaginal infection. Specific inclusion and exclusion criteria are outlined in Table 1. All three 
studies compared a placebo control to an oral probiotic group. The probiotic used in the RCT by 
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Nouraei et al. was protexin. Anukam et al. and Martinez et al. both used Lactobacillus 
rhamnosus GR-1 and Lactobacillus reuteri RC- 14 as the probiotics treatment. All three studies 
contained dichotomous data that could be used to calculate RBI, ABI, and NNT. 
 In the RCT by Nouraei et al., 90 women who had been diagnosed with VVC were 
randomly assigned to either the fluconazole + placebo group (n= 45) or the fluconazole + 
protexin group (n= 45) to determine the effectiveness of oral probiotics in conjunction with 
fluconazole in the treatment of VVC symptoms. Patients received two 150 mg fluconazole and 
twenty placebo or protexin capsules, depending on their assigned group.  Two protexin or 
placebo capsules were administered per day, one in the morning and one in the evening, after 
meals. Medications were distributed in a double-blinded manner. On days 5-7 after the start of 
treatment patients were reevaluated for cure rate. Of the expressed symptoms (itching, cheesy 
vaginal discharge, dysuria, dyspareunia, vulvar erythema and edema), a significant difference in 
the reduction of dysuria symptoms (P = 0.02) were found. The fluconazole-protexin combination 
proved to be more effective in the treatment of VVC associated dysuria than the fluconazole-
placebo group. Relative benefit increase (RBI) was calculated to be 69.5% and absolute benefit 
increase (ABI) was calculated to be 33.2% (Table 2). Numbers needed to treat (NNT) was 
calculated to be 4 (Table 2), meaning that for every 4 patients with VVC who were treated with 
fluconazole in combination with Protexin, 1 more will have a resolution in dysuria symptoms 
than the control group. All patients who entered into the study successfully completed all 
treatments and none were lost to follow up. While the majority of patients reported no adverse 
drug reactions, 6.7% of the fluconazole + placebo group reported nausea associated with their 
treatment.2  Number needed to harm (NNH) was calculated to be -15, meaning that for every 15 
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patients treated with fluconazole + Protexin, one fewer patients will have side effects than 
compared to the control group (Table 3). 
 In the study by Anukam et al., 59 women who had been diagnosed with acute VVC were 
randomized into two groups based on age and previous history of VVC. One group received 
fluconazole + placebo (n= 20) and the remaining received fluconazole + L. rhamnosus GR-1 and 
L. reuteri RC-14 (n= 39) to determine to effectiveness of oral probiotics in combination with 
fluconazole in the treatment of VVC symptoms. Patients received one 150mg oral dose of 
fluconazole plus either a daily placebo capsule or a daily probiotic capsule consisting of 5 billion 
L. rhamnosus GR-1 and L. reuteri RC-14  live organisms depending on their treatment group.3 
Treatments were distributed in a double blinded manner for 3 months. Patients were reassessed 
at day 7 to document proof of cure and continued to follow up at 1 month, 2 months, and 3 
months to assess their status. At each visit symptoms and cure rate were assessed based on 
patient answered questionnaires, which focused on the day the patient felt as though they 
obtained relief of symptoms (day 1 to day 7) and report of any side effects or recurrent infections 
during the 90 day study period, as well as 2 vaginal swabs that were tested for yeast 
microscopically and by culture. The final vaginal swabs, taken at 3 months, were further 
assessed using bacterial and fungal DNA extraction and species specific primers for PCR.  
 The results of this study were severely hindered by a lack of full compliance by the 
subjects. At the conclusion of the study 56% of patients were lost to follow up. Of the original 59 
patients, 47 reported on day 7 (33 in the probiotic group and 14 in the placebo) and only 26 
patients returned on day 30 and 90 (19 in the probiotic group and 7 in the placebo group). All 
results were calculated using the data collected on day 7 from the patients who remained in the 
study on day 90. Unfortunately, due to challenges faced by the study design, the research was 
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unable to show a significant reduction of symptoms between the placebo and probiotic group. On 
day 7 of the study 47% of the probiotic group reported a resolution of symptoms as compared to 
14% of the placebo group3 (p=0.2794). The data demonstrated a relative benefit increase (RBI) 
of 231.5% and an absolute benefit increase of 33.1% (Table 2).  The number needed to treat 
(NNT) was 4, meaning that 4 patients needed to be treated with fluconazole + L. rhamnosus GR-
1 and L. reuteri RC-14 in order for 1 more patient to experience a resolution of VVC symptoms 
(Table 2).  
 Of the patients who followed up for the extent of the study, few reported side effects of 
treatment. While the reported symptoms could not be directly correlated to the treatments, a few 
patients in each group reported a single episode of headache and nausea during the 90 day 
treatment window.3 Because the exact number of patients who reported side effects was not 
disclosed, a number needed to harm (NNH) statistic could not be calculated. 
In the study Martinez et al., 55 women who had been diagnosed with VVC by a positive 
Candida culture were randomly dived into two groups, the fluconazole + placebo (n= 26) and the 
fluconazole + L. rhamnosus GR-1 and L. reuteri RC-14 (n=29), to determine to effectiveness of 
oral probiotics in combination with fluconazole in decreasing the symptoms associated with 
VVC. Participants received a single 150mg dose of fluconazole plus either 2 capsules of L. 
rhamnosus GR-1 and L. reuteri RC-14 (each capsule containing 1 x109 viable cells4) or 2 placebo 
pills, depending on their treatment group. Treatments were distributed every morning in a double 
blinded manner for 28 days. Patients were reassessed at day 28 based on patient report of 
symptom resolution. A statistically significant difference was seen between the two groups; 26 
patients in the probiotic group (n= 29) reported resolution of vaginal discharge and at least one 
symptom (itching, burning, dyspareunia, and dysuria) where as only 17 on the control group 
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(n=26) reported a resolution of symptoms4 (p= 0.03). The dichotomous data in this study 
displays a relative benefit increase (RBI) of 37.2% and an absolute benefit increase (ABI) of 
24.3% (Table 2). The number needed to treat (NNT) was found to be 5 (Table 2), meaning that 5 
patients with VVC need to be treated with Fluconazole + L. rhamnosus GR-1 and L. reuteri RC-
14 in order for 1 to have a relief from symptoms.   
While side effects could not be directly correlated to any treatment methods within the 
study, two subjects in the fluconazole- probiotic group reported an increase in appetite, one 
reported a single episode of light stool and another reported one headache during treatment.4 
Based on reported side effected the number needed to harm (NNH) is 8, meaning that for every 8 
patients treated with Fluconazole + L. rhamnosus GR-1 and L. reuteri RC-14 , 1 more will 
experience an adverse reaction than compared to the control group(See Table 3). 
TABLE 2: Treatment effects 
RCT RBI ABI NNT p-value 
Nouraei (2012) 69.5% 33.2% 4 0.02 
Anukam (2009) 231.5% 33.1% 4 0.28 
Martinez (2009) 37.2% 24.3% 5 0.03 
 
TABLE 3: Side effects 
RCT CER EER RRI ARI Probiotic vs. Control NNH 
Nouraei (2012) 6.7% 0.0% -1 -6.7 Control group -15 
Martinez (2009) 0.0% 13.8% Error 13.8% Probiotic group 8 
 
DISCUSSION 
 Traditionally VVC has been treated with oral azoles. However, recent studies have shown 
that the addition of probiotics to treatment regiments may prove to be quite useful. Probiotics are 
live microorganisms which are similar to those naturally found in the human body, and therefore 
thought to be beneficial to human health.2 Lactobacilli species, such as L. rhamnosus and L. 
McDaid, Fluconazole and Probiotics 10 
 
reuteri, can found within vaginal flora.2 Studies show that these probiotics play an important role 
in suppressing potential vaginal pathogen.2 
 The studies in this systematic review analyze probiotic use in combination with 
fluconazole in the treatment of VVC. Results were deemed significant based on symptom 
reduction in the probiotic group when compared to the placebo group if the p value was shown to 
be < 0.05. While two studies proved to have significant results, the study by Anukam et al. was 
significant hindered by loss to follow up. After a 37% reduction in patient follow up at day 7, 
and further reduction of 56% at day 90, the sample size proved too small to provide statistically 
significant results limiting the validity of this study.  
 Although some studies have shown probiotics to hold significant benefit in certain health 
conditions this has not been evaluated by the FDA and is therefore has not been approved as a 
treatment in any disease.6 
 Due to the lack of FDA recognition, little research has been done regarding the side 
effects and warnings associated with probiotics. As of now it is believed that they are relatively 
harmless to healthy individuals and that the majority of patients do not suffer any side effects 
associated with usage. But because little is known about the actual affects of probiotics it is 
suggested that immunocompromised patients refrained from using probiotics.6   
Because probiotics are not considered a treatment for disease approved by the FDA, few 
health insurance plans are willing to cover the cost. Fortunately probiotics are relatively 
inexpensive, averaging around $20 per bottle.  Traditional fluconazole treatment tends to be 
rather inexpensive as well, ranging from $4-12 on average.7 The low costs of these products 
make treatment much more accessible to patients. 
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CONCLUSION 
 Although the majority of the studies in this systematic review supported the proposed 
hypothesis, the study by Anukam et al. was severely hindered by patient compliance and loss to 
follow up.  Due to personal hardships faced by these patients in their home country of Nigeria, it 
proved difficult for this population to follow through with the study. The study suggested that 
patients lacked a great understanding of the condition and the purpose of the study. For 
significant results to be determined it is essential that larger studies with strict protocols and 
extensive patient education be conducted in an attempt to prevent such poor results. Because of 
this, it is necessary to say that results were inconclusive as to whether or not oral probiotics in 
conjunction with fluconazole reduce symptoms among patients suffering from vulvovaginal 
candidiasis. 
 Future study is warranted to test a wider variety of oral probiotics and determine their 
effect in treating the symptoms of VVC. While all probiotics work in a similar manner, it is 
important to clarify the treatment outcomes of each probiotic strain so that it is not assumed all 
hold the same efficacy in VVC symptom reduction. 
 With the expansion of the medical field and the need for new treatments to battle the 
rising rate of drug resistance it is likely that this topic will be further explored in future studies
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